Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-640P represents a pseudogene related to the U6 small nuclear RNA, which is a highly conserved, non-coding RNA component of the spliceosome complex involved in RNA splicing[3][1]. RNU6-640P is a pseudogene derived from the U6 small nuclear RNA (snRNA), which normally serves as a catalytic component of the spliceosome responsible for intron excision from pre-mRNA in eukaryotic cells[3][1]. Pseudogenes like RNU6-640P are genomic sequences similar to functional genes but are generally non-functional; they do not code for a functional RNA or protein product and are not considered traditional drug targets or receptors[2]. While pseudogenes may have regulatory roles or indirect involvement in diseases (such as acting as miRNA decoys in some contexts), there is no known evidence that RNU6-640P is directly linked to disease mechanisms, drug interactions, or biomarker utility[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 640, pseudogene (RNU6-640P).